An abstract based on the studies that were performed earlier this year at Hospital de la Santa Creu i Sant Pau, Barcelona, has both been accepted for display and selected by a jury for oral presentation at the international congress EuroMedLab (IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine). The congress is held for the 24th time between November 28 and December 2 in Munich.

-It is very good that the abstract has both been accepted and chosen for presentation. The congress is one of the most important worldwide with regards to laboratory medicine, and the selection shows that the studies have generated interesting and solid new evidence. This will also give us good marketing at this important event, says Joen Averstad, CEO of Hemcheck.

Read more at: http://www.euromedlab2021munich.org/

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.